Alzamend Neuro, Inc. (NASDAQ:ALZN – Get Free Report) shares traded up 2.5% during trading on Tuesday . The company traded as high as $0.91 and last traded at $0.89. 10,198 shares were traded during mid-day trading, a decline of 68% from the average session volume of 32,360 shares. The stock had previously closed at $0.87.
Alzamend Neuro Stock Performance
The firm’s 50-day moving average price is $0.95 and its two-hundred day moving average price is $2.67. The stock has a market cap of $6.34 million, a price-to-earnings ratio of -0.59 and a beta of -0.13.
Institutional Inflows and Outflows
Alzamend Neuro Company Profile
Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.
- Five stocks we like better than Alzamend Neuro
- What Are Growth Stocks and Investing in Them
- Is the dip in Atlassian stock a sneaky buy opportunity?
- How to Invest in EV Charging Stations
- Caterpillar stock hits new highs; time to ring the register?
- What is ChatGPT Stock? How to Invest in It
- 5 medical stocks growing earnings by triple digits
Receive News & Ratings for Alzamend Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alzamend Neuro and related companies with MarketBeat.com's FREE daily email newsletter.